Why Ligand Pharmaceuticals Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Ligand Pharmaceuticals (NASDAQ: LGND  ) has received the dreaded¬†one-star ranking.

With that in mind, let's take a closer look at Ligand and see what CAPS investors are saying about the stock right now.

Ligand facts

Headquarters (founded)

La Jolla, Calif. (1987)

Market Cap

$437.9 million



Trailing-12-Month Revenue

$31.4 million


CEO John Higgins
CFO John Sharp

Return on Equity (average, past 3 years)



$12.4 million / $28.3 million


Eli Lilly
Roche Holding

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 32% of the 129 members who have rated Ligand believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, succinctly summed up the Ligand bear case for our community:

For years I couldn't understand why Ligand wasn't getting any love for their deep and extensive pipeline that had led to many approved drugs. Then after seeing revenues fail to materialize quarter after quarter, I understood that the company was incapable of extracting shareholder value from their partnerships. Now it seems that a new generation of traders has their eye on the Captisol platform as an apparent pathway to profitability, but I remain skeptical. Revenues upticked to [$13.6M] last quarter but the breakdown was typically opaque. The 2013 revenue guidance was a disappointing [$41-$44M]. ... The share price has risen nicely so far in 2013 but I think Ligand doesn't qualify for the buy and hold category.

If you want market-topping returns, you need to protect your portfolio from any undue risk. So, what macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2312791, ~/Articles/ArticleHandler.aspx, 9/28/2016 11:18:27 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
LGND $102.44 Up +2.80 +2.81%
Ligand Pharmaceuti… CAPS Rating: ***
LLY $80.71 Down -0.17 -0.21%
Eli Lilly and Co. CAPS Rating: ***
MRK $63.30 Up +0.73 +1.17%
Merck and Co. CAPS Rating: ****